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and adalimumab (Subcutaneous). The objective of this study was to compare the 
dispensation channel of anti-TNFs used in IBD across European (EU) top 5 coun-
tries. Methods: We analyzed dispensation conditions using IMS data from 2011 
and official local official websites, France (Haute Autorité de Santé and Health insur-
ance drugs database), Italy (Agenzia Italiana del Farmaco), Spain (Ministerio de 
Sanidad Servicios Sociales e Igualdad), Germany (Gemeinsamer Bundesausschuss), 
United Kingdom (Department of Health). Results: In UK, Spain, Italy, both inflixi-
mab and adalimumab dispensation were restricted to hospital channel. In Germany, 
both infliximab and adalimumab can either be dispensed through retail and hos-
pital channels. In France, adalimumab was available either in hospital and retail 
channels under exceptional status, and infliximab was dispensed through hospital 
channels only. The differences across countries could not be related to products 
labels as they are all approved under European Medicines Agency (EMA) centralized 
procedure. ConClusions: It is unlikely that the gaps observed are only related to 
differences in health care services organization but rather budget constraint like 
in UK, Italy and Spain. In Germany and France, the two leading EU pharmaceuticals 
markets this is not yet the case. Hospital dispensation channel of biologics and 
biosimilars is a new way to generate savings mainly through tenders.
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objeCtives: The cost of paediatric gastroenteritis is poorly documented in Asia. 
This analysis reports findings of a survey on disease burden, cost and productivity 
loss caused by paediatric gastroenteritis in Malaysia and Viet Nam. Methods: A 
survey was conducted between August 2012 and April 2013 targeting respondents 
in public spaces in Hanoi and Bac Giang, Viet Nam and Klang Valley, Malaysia. The 
surveys were self-administered and collected information on demographics, disease 
burden, cost and productivity loss. Descriptive analysis was conducted to report the 
overall findings using STATA SE 11.2. Results: Survey questionnaires were com-
pleted by 245 and 307 respondents from Malaysia and Viet Nam, respectively. Over 
90% of the respondents were parents of children below 10. Overall, 69% reported 
that their children experienced gastroenteritis requiring physician visits and 28% 
reported episodes requiring hospital admissions. Differences were noted in the 
treatment seeking patterns between the two countries. These differences influenced 
cost and productivity loss to the families of affected children. In Malaysia, a large 
proportion of parents (41.2%) reported hospitalisation cost to be more than USD 350 
whereas in Viet Nam, a majority (74.6%) reported hospitalisation cost less than USD 
34. Among these, 52.9% and 30.5% of Malaysian and Vietnamese parents paid out-of-
pocket for hospital admission, respectively. The majority reported days off work of 2 
to 5 days, however more parents in Viet Nam (23.7%) required greater than 6 days off 
work to care for their affected child compared to Malaysia (3.9%). ConClusions: 
Gastroenteritis has an impact on cost and productivity loss to parents of affected 
children in Malaysia and Viet Nam. However, there were several differences noted 
likely due to differences in GDP, health system and cultural factors.
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objeCtives: To assess the impact of inflammatory bowel diseases (IBD) in the 
Italian general population: incidence and time trends from 2003 to 2009, as well 
as population characteristics. Methods: A retrospective observational study was 
conducted in Lombardy, an Italian region with about 10 million of inhabitants, using 
health care administrative databases of the national health care system (HS) which 
provides universal coverage. The main administrative databases were integrated in 
a data warehouse called DENALI using probabilistic record linkage. New cases of 
Crohn’s Disease (CD) and Ulcerative Colitis (UC) were identified in the adult popu-
lation between January 1, 2003 and December 31, 2009. Annual age-standardized 
incidence rates were computed separately for CD and UC using the population 
living in Lombardy at 2001 census. Moreover we evaluated patients’ baseline main 
characteristics, coexisting chronic conditions and survival at December 31, 2009.  
Results: The annual incidence rate per 100,000 person-years of IBD was 15.6 (95%CI 
15.2-15.9); UC and CD incidences were 9.7 (9.4-10.0) and 5.9 (5.7-6.1) respectively. 
Incidence rates of both diseases were higher in men than in women. CD incidence 
was highest in subjects aged 20-24 (9.2, 95%CI 8.1-10.2) and decreased with age, 
while UC incidence was stable in the 20-65 year-old population. No time trends in 
UC and CD incidences were observed from 2003 to 2009, both in the whole study 
population and in gender and age-specific subgroups. The mean age at CD diag-
nosis was 44 years (±16.6 sd), which was lower than that at UC diagnosis (46 ± 16.6, 
p< 0.0001). During a mean follow-up time of 3.4 years (± 2.0) 2.2% of IBD patients 
died. ConClusions: Our study provides updated estimates on current epidemiol-
ogy of IBD in Italy. IBD incidence in Lombardy is lower than in northern Europe and 
the data confirm that UC incidence is higher than that of CD.
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examining aminosalicylates (n= 23), corticosteroids (n= 10), immunosuppressants 
(n= 15), biologics (n= 16) and kinase inhibitors (n= 1). Baseline patient characteristics, 
study design and outcomes were extracted, including: adverse events (AE) (reported 
in n= 24 studies), serious AE (n= 25), deaths (n= 23), clinical remission (n= 49), clini-
cal response (n= 33) and mucosal healing (n= 11). Eleven different disease activity 
scales and four different endoscopic scales were used. The mean age of included 
patients ranged from 27 to 51, and the percentage of males from 28.6% to 87.5%. Due 
to large differences and different scales used for reporting efficacy it is not feasible 
to report the range across different scales. Safety endpoints were also reported 
inconsistently. The results per outcome are presented in a narrative way per treat-
ment class. ConClusions: A comprehensive SLR performed which identified 65 
RCT reporting on the efficacy and safety of pharmacological treatments in moderate 
to severe UC patients. Differences in patient population, disease severity, disease 
activity scales and trial duration are explored and presented.
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objeCtives: To assess the impact of new HCV drugs pricing strategy on the number 
of potential treated/cured patients and on the Italian Healthcare Service budget, 
using a simplistic model to design different scenarios for second generation direct 
antiviral agents (DAAs). Methods: We calculated the HCV drugs budget and the 
number of patients for setting a base case by summing a) AIFA values for HCV 
dual therapy drugs to assess the number of patients currently treated; b) triple 
therapy number of patients estimated from AIFA budget (210.000.000€ in total). 
We performed budget scenarios on two variables: 1) pricing strategy of more effec-
tive DAAs; 2) total HCV drugs budget. We calculated the number of treated and 
responder patients, considering only genotype 1 HCV to maintain a comparability 
between base case and future scenarios with new DAAs. Results: The number of 
patients to be cured with stable budget vs base case are: 1) 9.000 (+56% vs. base case) 
with parity price vs. triple therapy; 2) 7.500 (+30% vs. base case) in case of a 20% 
premium price that would allow 8.300 patients to be treated. Assuming to double 
the allocated budget from payers (420.000.000€ ) and to reduce the new DAAs price 
by a 20%, 25.000 patients will be treated and 22.500 (+291% vs. base case) will be 
cured. ConClusions: This simplified analysis shows that more effective drugs can 
significantly increase the number of patients who could be treated and cured. In 
order to support these results, efforts from both payers (higher budget) and pharma 
companies (lower prices) are needed.
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objeCtives: The objective of this study is to examine health care expenditures asso-
ciated with Gastro-esophageal Reflux Disease (GERD) among elderly with Chronic 
Obstructive Pulmonary Disease (COPD) and understand the explanatory factors 
associated with incremental expenditures associated with (GERD). Methods: The 
study utilized retrospective cross-sectional design. Data were extracted from multiple 
years (2006-2009) of the Medicare Current Beneficiaries Survey (MCBS). The analytical 
sample consisted of community dwelling elderly individuals with COPD (n = 3,821) 
identified using appropriate International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) codes. The key independent variable was defined 
as presence or absence of GERD. T-tests and ordinary least squares regressions (OLS) 
on log-transformed total health care expenditures were performed to analyze the 
association between health care expenditures with GERD among individuals with 
COPD. Blinder-Oaxaca decomposition analysis was performed to estimate contribu-
tion of factors towards explaining the excess health care expenditures. Results: 
Among elderly individuals with COPD, the annual average health care expenditures 
were higher for those with GERD ($36,793 ± $1,387) as compared to those without 
GERD ($24,722 ± $800). Individuals with GERD had poorer health status, low physi-
cal activity profile, and higher rates of obesity. Furthermore, the rates of depression 
and anxiety were significantly higher among individuals with GERD compared to 
those without GERD. A decomposition technique revealed that nearly 30.9% of the 
incremental health care spending associated with GERD was due to the differences in 
characteristics such as Charlson’s comorbitity score (17.5%), perceived health status 
(7.13%) and depression (5.85%). ConClusions: Our findings highlight the burden 
of comorbid conditions among those with COPD and GERD. This study reinforces the 
need to modify the care-delivery model from single-disease care approach to inte-
grated/ multiple diseases care approach to manage the complex comorbid diseases, 
which may ultimately reduce the excess health care expenditures.
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objeCtives: In The Netherlands, the funding for some high cost drugs and particu-
larly biologics was transferred in 2012 to hospital pharmacy dispensation channel. A 
European study forecast (2012-2016) shown hospital dispensation as a very effective 
policy to reduce budget impact of branded biologics and increase savings related 
to biosimilars. Two biologics (anti-TNFs) are indicated for Inflammatory Bowel 
Disease (IBD) in EU with different mode of administration: infliximab (Intravenous) 
